Disclaimer: This article provides general information about EU Regulation 536/2014 and is not legal advice. Regulatory requirements vary by member state and by the specific characteristics of each clinical trial. Consult a qualified legal or regulatory professional for guidance on your specific situation.
EU Clinical Trial Regulation 536/2014: A Practical Compliance Guide for Sponsors and Investigators
Overview
On 31 January 2022, Regulation (EU) No 536/2014 (the Clinical Trials Regulation, or CTR) became applicable across the European Union, replacing the Clinical Trials Directive 2001/20/EC that had governed clinical trials in the EU since 2001.
The CTR applies to clinical trials on medicinal products for human use conducted in EU member states. Its reach extends beyond EU-based organisations: if a trial is conducted outside the EU but the data is intended to support a marketing authorisation application in the EU, the trial must follow principles equivalent to the CTR as regards participant rights, safety, and data reliability.
The regulation’s core objectives are to harmonise submission and assessment procedures across the EU, reduce administrative burden for multinational trials, strengthen transparency, improve participant protection, and create a more consistent framework for regulatory supervision. All of these objectives are pursued through a centralised system: the Clinical Trials Information System (CTIS).
Key Requirements
Sponsor obligations
The sponsor is the legal entity responsible for initiating, managing, and financing a clinical trial. Under CTR 536/2014, the sponsor’s primary obligations include submitting the trial application via CTIS, maintaining insurance or indemnification coverage for trial participants, ensuring that the investigational medicinal product is manufactured in compliance with GMP, and meeting all safety reporting timelines.
Sponsors based outside the EU must appoint an EU legal representative, per Article 74 of the CTR. This representative assumes legal responsibility for the sponsor’s obligations under the regulation within the EU.
The sponsor must also publish the results of a clinical trial within one year after the end of the trial. This transparency obligation, introduced under Article 37 of the regulation, replaced a widely non-enforced version of the same requirement under the old Directive.
Investigator and site obligations
Investigators and participating sites carry specific obligations under the CTR, including ensuring that informed consent is obtained before any trial procedure, that participants meet the protocol’s inclusion and exclusion criteria, that the trial is conducted in accordance with the approved protocol, and that adverse events are reported according to the timelines defined in the regulation and the protocol.
Investigators are also responsible for ensuring that the trial master file (TMF) for their site is maintained and available for inspection by national competent authorities or the EMA at any time during and after the trial.
CTIS submission requirements
All submissions related to a clinical trial (initial application, substantial modifications, safety reports, and results) must be made through CTIS. The system covers all EU/EEA member states in a single submission portal.
Part I of the CTIS application covers aspects assessed jointly by member states (clinical and scientific aspects of the protocol, IMP dossier, and GMP compliance). Part II covers aspects assessed at member-state level (local ethical committee review, subject recruitment arrangements, and national regulatory requirements). Sponsors should carefully assess the pertinence and feasibility of the planned trial before submission, and ensure that SUSAR reporting to EudraVigilance is set up and tested before the first participant is enrolled.
Transparency requirements
All submissions made via CTIS are, by default, publicly accessible through the CTIS public portal unless specific justification for confidentiality is accepted. This covers protocols, investigator brochures, results summaries, and inspection findings. Updated transparency rules became applicable on 18 June 2024 with the launch of a revised version of the CTIS public portal.
Participant protection
The regulation includes reinforced measures to protect the rights, safety, and wellbeing of trial participants. Sponsors are required to provide clear and accessible information to participants, especially those considered vulnerable, such as minors, incapacitated adults, or individuals in emergency situations. A damage compensation mechanism in accordance with national legislation must be in place before a trial can begin.
Compliance Requirements
| Requirement | Who is responsible | Key reference |
|---|---|---|
| CTIS submission (Part I and II) | Sponsor | Articles 5, 6, 7 CTR |
| Informed consent documentation | Investigator/site | Articles 28-35 CTR |
| Insurance/indemnification | Sponsor | Article 76 CTR |
| SUSAR reporting to EudraVigilance | Sponsor | Article 42 CTR |
| Annual safety reporting (ASR/DSUR) | Sponsor | Article 43 CTR |
| Trial results publication (within 1 year) | Sponsor | Article 37 CTR |
| GMP compliance for IMP | Sponsor | Article 61 CTR |
| TMF maintenance and availability | Investigator/site | Article 57 CTR |
| EU legal representative (non-EU sponsors) | Sponsor | Article 74 CTR |
| EUDAMED registration (where applicable) | Sponsor | CTR + IVDR/MDR |
Documentation
Trial master files must be structured, maintained in real time, and available for regulatory inspection at any point during the trial and for a minimum period after the trial ends (typically 25 years for medicinal products intended for adults, or longer for paediatric medicines). Electronic TMFs are accepted and increasingly expected; inspectors now routinely assess digital systems for audit trail integrity and access controls.
Reporting timelines
Suspected Unexpected Serious Adverse Reactions (SUSARs) must be reported to EudraVigilance within 7 days for fatal or life-threatening events, and within 15 days for all other SUSARs. Annual safety reports covering aggregate safety data for the investigational medicinal product must be submitted while the trial is ongoing.
Penalties and Consequences
Penalties for non-compliance with CTR 536/2014 are set at member-state level, not uniformly by the regulation itself. The CTR requires member states to establish penalty regimes, and these vary across the EU.
As an illustration of the range that applies in some member states: penalties can include imprisonment from one month to two years and a fine from €500 to €250,000, depending on the nature and severity of the violation. Violations relating to participant safety or fraudulent data tend to attract the most severe penalties.
Beyond criminal or administrative penalties, non-compliance can result in suspension or termination of the trial by the member state or the EMA, withdrawal of marketing authorisation for products developed from non-compliant trial data, reputational consequences affecting future trial authorisations across the EU, and exclusion from public funding for research.
Practical Implementation
Step 1: Confirm whether your study falls under the CTR
Not all studies are clinical trials under CTR 536/2014. The regulation applies specifically to trials on medicinal products for human use. Non-interventional studies, medical device studies (which fall under MDR/IVDR), and purely observational research generally fall outside its scope. The European Commission has published a decision tree in the CTR Q&A document (current version 7.1, March 2025) for making this determination.
Step 2: Register in CTIS and obtain a sponsor registration number
Sponsors must register in CTIS before submitting a trial application. Non-EU sponsors must appoint an EU legal representative first, since the representative’s details are required for registration.
Step 3: Prepare the dossier for CTIS submission
The trial dossier must include a completed protocol, the investigator’s brochure, informed consent form templates, subject information sheets, and the IMP dossier demonstrating GMP compliance. Structured data fields in CTIS require specific formats; the CTIS sponsor handbook (available from the European Medicines Agency) covers these in detail.
Step 4: Set up safety reporting infrastructure before enrolment
SUSAR reporting to EudraVigilance requires a registered organisation in EudraVigilance, technical setup for electronic submissions, and trained staff. This infrastructure should be tested before the first participant is enrolled, not after.
Step 5: Build the TMF from day one
Trial master files should be structured and populated from the moment a trial is authorised, not retroactively assembled ahead of an inspection. Whether paper or electronic, the TMF must reflect the actual chronology of the trial’s conduct.
Step 6: Plan results publication into the trial timeline
Results publication within one year of trial completion is a legal obligation, not a best practice recommendation. Sponsors should build results reporting into their post-trial close-out timeline explicitly, with a named person responsible for the submission.
Frequently Asked Questions
Does the CTR apply to trials sponsored by non-EU companies? Yes, if the trial is conducted in an EU member state or if the data will be used to support a marketing authorisation application in the EU. Non-EU sponsors must appoint an EU legal representative per Article 74.
What happens to trials that were authorised under the old Directive? Trials authorised under Directive 2001/20/EC had until 31 January 2025 to transition to the CTR framework via CTIS. Trials not transitioned by that deadline are no longer operating under a valid legal framework.
Can a sponsor submit to multiple EU member states through a single CTIS application? Yes. CTIS allows a single application covering multiple member states simultaneously. Part I is assessed jointly; Part II is assessed separately by each member state’s national authority and ethics committee.
What is a SUSAR, and who is responsible for reporting it? A Suspected Unexpected Serious Adverse Reaction is a serious adverse reaction to the investigational medicinal product that is both unexpected (not listed in the IB) and suspected to be causally related to the IMP. The sponsor is responsible for reporting SUSARs to EudraVigilance, within 7 days for fatal or life-threatening events and 15 days for others.
Does the CTR apply to medical device trials? No. Clinical investigations of medical devices and in vitro diagnostic devices are governed by the MDR (EU) 2017/745 and IVDR (EU) 2017/746 respectively, not by CTR 536/2014.
References
- Regulation (EU) No 536/2014, full text (EUR-Lex)
- European Commission: Clinical Trials Regulation 536/2014 overview
- European Commission: CTR 536/2014 practical guide
- CTR Q&A document, version 7.1 (March 2025)
- CTIS public portal
- EudraVigilance (safety reporting)
- Implementing Regulation (EU) 2017/556: GCP inspection procedures
Sources
- EUR-Lex, “Regulation (EU) No 536/2014 of the European Parliament and of the Council”
- European Commission, “Clinical Trials Regulation EU No 536/2014”
- European Commission, “Clinical Trials Regulation 536/2014 in practice”
- FAMHP Belgium, “EU Regulation 536/2014”
- Codex Clinical Research, “Regulation (EU) No 536/2014”
- HAI/BUKO Pharma-Kampagne, “Clinical Trial Regulation in Europe” (2022)
- Certara, “Clinical Trials Regulation EU No. 536/2014: The Impact on Annual Safety Reporting”